United Theranostics Appoints Amber Woodward-Smith Chief Financial Officer to Support Nationwide Expansion

Experienced healthcare finance executive brings expertise in scaling clinical networks, strategic partnerships and financial operations

BETHESDA, Md., Oct. 29, 2026 /PRNewswire/ -- United Theranostics, a leader in advanced molecular imaging and precision radiopharmaceutical cancer therapy, today announced the appointment of Amber Woodward-Smith as Chief Financial Officer. With more than two decades of experience in healthcare finance, acquisitions, strategic planning and operational expansion, Woodward-Smith will play a key role in supporting the company's goal of expanding access to radiopharmaceutical therapies through outpatient physician practices in all 50 states.

Woodward-Smith joins United Theranostics at a pivotal stage in its growth, as the company expands its network of outpatient cancer treatment centers and develops strategic partnerships to make highly specialized cancer care more accessible to patients in their own communities.

"Amber has spent her career helping healthcare organizations grow, bringing together the financial expertise, operational discipline and strategic vision needed to build successful clinical networks," said Rob Cherney, Chief Executive Officer of United Theranostics. "Our goal is to bring Nuclear Oncology and meaningful access to oncologists, specialists, and the patients they treat regardless of where they live, and Amber brings exactly the kind of leadership needed to help make that possible."

Woodward-Smith most recently held senior financial leadership positions at Sarah Cannon Research Institute, a leading oncology research organization. During her tenure, she played an important role in the formation and integration of a major joint venture involving HCA Healthcare and McKesson's US Oncology Research.

Her experience also includes overseeing financial operations, developing processes across complex healthcare organizations, negotiating acquisitions and supporting the integration of clinical services.

United Theranostics is working to transform how patients access precision oncology by bringing sophisticated molecular imaging and targeted radiopharmaceutical therapies beyond major academic medical centers and into local communities. Its integrated model combines advanced PET/CT and SPECT/CT imaging, personalized treatment planning, radiopharmaceutical therapies, clinical research and coordinated patient support.

Through its growing network of outpatient centers and Nuclear Oncology Centers of Excellence, the company aims to reduce geographic barriers to specialized treatment while providing patients with access to innovative therapies and experienced clinical teams closer to home.

"United Theranostics is addressing one of the most important challenges in modern cancer care: ensuring that patients can access advanced treatments without geography becoming a barrier," said Woodward-Smith. "I've spent much of my career helping healthcare organizations expand their reach while maintaining the financial and operational strength needed to deliver exceptional care. I'm excited to bring that experience to a company with such a clear vision for making precision cancer treatment more accessible nationwide."

As part of the leadership transition, Seth Van Voorhees will move from Chief Financial Officer to Chief Development Officer.

About United Theranostics

United Theranostics is a national healthcare organization dedicated to expanding access to advanced molecular imaging and precision radiopharmaceutical cancer therapy. For more information, visit www.unitedtheranostics.com.

Media Contact:
Jake Messier, MBA
774-368-0094
[email protected]  

SOURCE United Theranostics